Of those reporting no SGLT2i use at baseline, increasing numbers of participants started SGLT2i during the trial, with a greater proportion starting SGLT2i in the placebo (approximately 10% at 18 months and approximately 20% at 36 months) than in the semaglutide group (approximately 5% at 18 months and approximately 10% at 36 months
(Table S3) Subgroup, sensitivity and specificity analyses based on the treated population Subgroup analyses were performed focusing on age, comorbidities such as hypertension and advanced CKD, and medication use (Fig
Why Weight Management is a Primary Strategy for OSA Managing weight is key to treating OSA
These episodes are brief and typically require no intervention
However, data are scant and controversial, resulting in limited efforts to study the effect of nutritional interventions on GSH status
Growth Hormone Signaling Pathways